Evidence map›Paper›PMID 24528685›Full record

GuidelineJournal of clinical lipidology

An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report.

Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members

2 registry-linked trialsAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02593487. Cited by 138 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02593487 phase4unknown status

Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia

Ran2015Enrolled300Registered outcomes1Posted comparisons0ConditionsCoronary Heart Disease, HyperlipemiaArmsRosuvastatin 10mg/d group, Rosuvastatin 20mg/d group
PMID 24595147PMID 17898099PMID 23428644PMID 24739590PMID 22584085PMID 18955731PMID 24465490other papers from this trial
Open the trial in the graph
NCT06929403 nacompletednot on this map

Effect of Dietary Supplement Containing Bergamot and Plant Sterols Extract on Serum Lipid Profile

TypeinterventionalSponsorIstanbul Bilgi UniversityRan2024 to 2025Enrolled61ConditionsDyslipidemia, Cardiac Disease, Cardiovascular DiseasesArmsDiet, Diet supplementation
3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.The Cochrane database of systematic reviews · 2018 · on this map
    Pooled it
  5. Pooled it
  6. Fibrates for primary prevention of cardiovascular disease events.The Cochrane database of systematic reviews · 2016 · on this map
    Pooled it
  7. Fibrates for secondary prevention of cardiovascular disease and stroke.The Cochrane database of systematic reviews · 2015
    Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An international panel of the International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia. The panel identifies non--high-density lipoprotein cholesterol as the major atherogenic lipoprotein. Primary and secondary prevention are considered separately. Optimal levels for atherogenic lipoproteins are derived for the two forms of prevention. For primary prevention, the recommendations emphasize lifestyle therapies to reduce atherogenic lipoproteins; drug therapy is reserved for subjects at greater risk. Risk assessment is based on estimation of lifetime risk according to differences in baseline population risk in different nations or regions. Secondary prevention emphasizes use of cholesterol-lowering drugs to attain optimal levels of atherogenic lipoproteins.

Indexed as

Health Planning GuidelinesInternationalitySocieties, MedicalAnticholesteremic AgentsAtherosclerosisDyslipidemiasHumansLife StyleRisk FactorsAnticholesteremic AgentsCholesterolDyslipidemiaLifestyle therapiesLifetime riskMetabolic syndromeStatins

Identifiers

PMID24528685

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.